Spots Global Cancer Trial Database for Safety of Everolimus and Pemetrexed in Lung Cancer Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety of Everolimus and Pemetrexed in Lung Cancer Patients
Official Title: A Phase I Study Investigating the Combination of Everolimus With Pemetrexed in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy
Study ID: NCT00434174
Conditions
Study Description
Brief Summary: This study will evaluate the safety of everolimus in combination with pemetrexed when used as treatment in patients with non small cell lung cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Novartis Investigative Site, Camperdown, New South Wales, Australia
Novartis Investigative Site, Melbourne, Victoria, Australia
Novartis Investigative Site, Leuven, , Belgium
Novartis Investigative Site, Hamburg, , Germany
Novartis Investigative Site, Koeln, , Germany
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Name: Novartis
Affiliation: Novartis
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
